Eosinophilic Fasciitis and Simvastatin
Arch Int Med 161:1456-1457, Choquet-Kastylevsky,G.,et al, 2001
Pachymeningitis and optic neuritis in Rheumatoid Arthritis: Successful Treatment with Cyclophosphamide
Clin Rheumatol 20:136-139, Yucel,A.E.,et al, 2001
The Expanding Spectrum of Herpesvirus Infections of the Nervous System
Brain Pathology 11:440-451, Kleinschmidt-DeMasters,B.K. &Gilden,D.H., 2001
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
The Effect of IFNB-1b on the Evolution of Enhancing Lesions in Secondary Progressive MS
Neurol 57:2185-2190, Brex,P.A.,et al, 2001
Safety of HMG-CoA Reductase Inhibitors: Focus on Atorvastatin
Cardiovasc Drugs Ther 15:211-218, Bernini,F.,et al, 2001
Uveal Effusion and Secondary Angle-Closure Glaucoma Associated with Topiramate Use
Arch Ophthalmol 119:1210-1211, Sankar,P.S., 2001
Welding-Related Parkinsonism
Neurol 56:8-13,4, Racette,B.A.,et al, 2001
HIV-associated Neurologic Disease Incidence Changes: Multicenter AIDS Cohort Study, 1990-1998
Neurol 56:257-260, Sacktor,N.,et al, 2001
Intraarterial Thrombolysis: Ready for Prime Time?
AJNR 22:55-58, Executive Committee of the ASITN, 2001
Hypertrophic Chronic Pachymeningitis as a Localized Immune Process in the Craniocervical Region
Neurol 56:107-109, Boller,B.,et al, 2001
Chorea and Antiphospholipid Antibodies: Treatment with Methotrexate
Neurol 56:137-138, Paus,S.,et al, 2001
Protocol Violations in Community-Based rTPA Stroke Treatment Are Associated with Symptomatic Intracerebral Hemorrhage
Stroke 32:12-16, Lopez-Yunez,A.M.,et al, 2001
Parkinsonism as the Presenting Manifestation of HIV Infection: Improvement on HAART
Neurol 56:278-279, Hersh,B.P.,et al, 2001
Risk Factors for Cerebral edema in Children With Diabetic Ketoacidosis
NEJM 344:264-269,302, Glaser,N.,et al, 2001
Calcium Antagonists for Ischemic Stroke
Stroke 32:570-576, Horn,J. &Limburg,M., 2001
Human Albumin Therapy of Acute Ischemic Stroke
Stroke 32:553-560, Belayev,L.,et al, 2001
Risk Factors for Sever Hemorrhagic Transformation in Ischemic Stroke Patients Treated with Recombinant Tissue Plasminogen Activator
Stroke 32:438-441, Larrue,V.,et al, 2001
Combined Intraarterial/Intravenous Thrombolysis for Acute Ischemic Stroke
AJNR 22:352-358, Keris,V.,et al, 2001
Reversible Posterior Leukoencephalopathy During the Treatment of Acute Lymphoblastic Leukemia
Neurol 56:388-391, Shin,R.K.,et al, 2001
Botulinum Toxin as a Biological Weapon
JAMA 285:1059-1070, Arnon,S.S.,et al, 2001
Deterioration Following Improvement with tPA Therapy: Carotid Thrombosis and Reocclusion
Neurol 56:568-570, Burgin,W.S. &Alexandrov,A.V., 2001
Suppression of Recurrent Transient Ischemic Attacks by a Statin Agent
Neurol 56:531-532, Alberts,M.J., 2001
Clinical Deterioration Following Improvement in the NINDS rt-PA Stroke Trial
Stroke 32:661-668, Grotta,J.C.,et al, 2001
Spontaneous Intracerebral Hemorrhage
NEJM 344:1450-1460, Qureshi,A.I.,et al, 2001
Most Commonly Asked Questions About Intra-arterial Thrombolysis
The Neurologist 7:127-131, Wechsler,L.R., 2001
Utilization of Intravenous Tissue-Type Plasminogen Activator for Ischemic Stroke at Academic Medical Centers
Stroke 32:1061-1068, Claiborne Johnston,S.,et al, 2001
Intravenous tPA for Ischemic Stroke Team Performance Over Time, Safety, and Efficacy in a Single-Center, 2-Year Experience
Stroke 32:1074-1078, Koennecke,H.,et al, 2001
Initial and Follow-up MR Imaging Findings in AIDS-Related Progressive Multifocal Leukoencephalopathy Treated with Highly Active Antiretroviral Therapy
AJNR 22:977-984, Thurnher,M.M.,et al, 2001
Benefits of Perfusion MR Imaging Relative to Diffusion MR Imaging in the Diagnosis and Treatment of Hyperacute Stroke
AJNR 22:915-921,806, Sunshine,J.L.,et al, 2001
Community Use of Intravenous Tissue Plasminogen Activator for Acute Stroke
Stroke 32:861-865, Katzan,I.L.,et al, 2001
Clinicopath Conf, Strychnine Poisoning, Case 12-2001
NEJM 344:1232-1239, , 2001
Why Are Stroke Patients Excluded from TPA Therapy?
Neurol 56:1015-1020, Barber,P.A.,et al, 2001
Cerebral Sinus Thrombosis with Tamoxifen
Neurol 56:1113-1114, Finelli,P.F. & Schauer,P.K., 2001
High-Density Lipoprotein Cholesterol and Ischemic Stroke in the Elderly
JAMA 285:2729-2735, Sacco,R.L.,et al, 2001
Effect of Early Interferon Treatment on Conversion to Definite Multiple Sclerosis: A Randomised Study
Lancet 357:1576-1582,1547, Comi,G.,et al, 2001
Statins for Stroke Prevention?
Lancet 357:1548-1549, Sandercock,P., 2001
Adverse Long-term Effects of Brain Radiotherapy in Adult Low-grade Glioma Patients
Neurol 56:1285-1290,1255, Surma-aho,O.,et al, 2001
Fulminant Liver Failure During Interferon Beta Treatment of Multiple Sclerosis
Neurol 56:1416, Yoshida,E.M.,et al, 2001
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1496-1504, Secondary Progressive Efficacy Clinical Trial of R, 2001
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1505-1513, Li,D.K.B.,et al, 2001
Safety of Intra-Arterial Thrombolysis in the Postoperative Period
Stroke 32:1365-1369, Chalela,J.A.,et al, 2001
Thrombolysis of Extracranial and Intracranial Arteries After IV Abciximab
Neurol 56:1582-1584, Houdart,E.,et al, 2001
Rescue Treatment with Abciximab in Acute Ischemic Stroke
Neurol 56:1585-1587, Lee,K.Y.,et al, 2001
CT Angiography in the Rapid Triage of Patients with Hyperacute Stroke to Intraarterial Thrombolysis: Accuracy in the Detection of Large Vessel Thrombus
J Comput Assist Tomogr 25:520-528, Lev,M.H.,et al, 2001
Risk of Stroke Associated With Abciximab Among Patients Undergoing Percutaneous Coronary Intervention
JAMA 286:78-82, Akkerhuis,K.M.,et al, 2001
PRISMS-4: Long-Term Efficacy of Interferon-B-1a in Relapsing MS
Neurol 56:1628-1636,1620, The PRISMS Study Group, 2001
Herpes Simplex Virus Encephalitis Complicating Myxedema Coma Treated with Corticosteroids
Neurol 56:1114-1115, Doherty,M.J.,et al, 2001
Cooling for Acute Ischemic Brain Damage (COOL AID)
Stroke 32:1847-1854, Krieger,D.W.,et al, 2001
Treatment with Tissue Plasminogen Activator and Inpatient Mortality Rates for Patients with Ischemic Stroke Treated in Community Hospitals
Stroke 32:1832-1839,1840, Reed,S.D.,et al, 2001